Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track AMPH with free AI briefings, catalyst countdowns, and dilution alerts.

AMPH · Amphastar Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$290.1M Cash on Hand

CF+ Cash Runway

Follow AMPH by email Get an email when AMPH pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AMPH, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jun 2026 · Phase 2/3 · Results Expected · Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Propose
Registry primary completion date, not a results date
Jan 2023 · Phase 2/3 · Results Expected · Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Propose
Registry primary completion date, not a results date
Dec 2019 · Phase 4 · Results Expected · Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versu
Registry primary completion date, not a results date
Oct 2014 · Phase 2 · Results Expected · Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers
Registry primary completion date, not a results date
Sep 2014 · Phase 2 · Results Expected · Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
Registry primary completion date, not a results date
Mar 2013 · Phase 3 · Results Expected · Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Albuterol	Asthma	Phase 3 · NCT00634829	Terminated
Epinephrine HFA-MDI (E004)	Asthma	Phase 3 · NCT01737905	Completed
albuterol HFA (Armstrong's)	Asthma	Phase 3 · NCT00635505	Terminated
Albuterol Sulfate Inhalation Aerosol	Asthma	Phase 3 · NCT00634517	Terminated
E004 (Epinephrine Inhalation Aerosol) HF	Asthma	Phase 3 · NCT01460511	Completed
Armstrong Albuterol Sulfate Inhalation A	Asthma	Phase 3 · NCT00634517	Terminated
E004 (epinephrine inhalation aerosol), 1	Asthma	Phase 1/2 · NCT01025648	Terminated
Epinephrine Inhalation Aerosol, HFA	Asthma	Phase 1/2 · NCT01188577	Completed
Histamine	Allergic Skin Reaction	Phase 2 · NCT01689363	Completed
Proventil-HFA	Asthma	Phase 2 · NCT01189396	Completed
Albuterol Sulfate	Asthma	Phase 2 · NCT02210806	Completed
A006	Asthma	Phase 2 · NCT01189396	Completed
Arm T2: Primatene Mist HFA	Asthma	Phase 2 · NCT01255709	Completed
Arm T1: Primatene Mist HFA	Asthma	Phase 2 · NCT01255709	Completed
Arm T Epinephrine Inhalation Aerosol HFA	Asthma	Phase 1/2 · NCT01737892	Terminated
Arm C: Primatene Mist (epinephrine inhal	Asthma	Phase 2 · NCT01255709	Completed

Also used in these trials (approved or third-party drugs, not AMPH's own candidates): Epinephrine Inhalation, Insulin Aspart, Hyaluronidase.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AMPH holds $290.1M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMPH files for a raise →

👥 Who Owns AMPH

Insiders 25.1% Institutions (303 holders) 68.7% Public and other holders 6.2%

Holder	Type	Shares	% of shares	As of
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER, Director · +149,472 options	Insider	9,817,731	23.08%	2026-03-15
BlackRock, Inc.	Institution (13G, 5%+)	5,333,463	12.54%	2025-09-30
Dimensional Fund Advisors LP	Institution (13G, 5%+)	2,305,107	5.42%	2026-06-30
Rong Zhou SENIOR EVP, PRODUCTION CENTER · +100,765 options	Insider	174,203	0.41%	2026-09-16
William J Peters CFO, EVP & TREASURER, Director · +121,071 options	Insider	168,707	0.40%	2026-09-21
Howard Lee Director · +17,365 options	Insider	159,350	0.37%	2026-06-01
Yakob Liawatidewi EVP CORP ADMIN CENTER, Director · +73,126 options	Insider	124,351	0.29%	2026-03-15
Floyd F. Petersen Director	Insider	71,368	0.17%	2025-12-11
Michael A Zasloff Director · +17,365 options	Insider	37,667	0.09%	2026-06-01
Diane G. Gerst Director · +17,365 options	Insider	31,899	0.07%	2026-06-01
Richard K Prins Director · +17,365 options	Insider	29,625	0.07%	2026-08-11
Gayle Deflin Director · +17,365 options	Insider	19,057	0.04%	2026-06-01

Share count 42,537,944 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AMPH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMPH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z